GSK launches $2.5 billion buyback, lifts sales target after stellar fourth quarter
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV ...
FiercePharma5h
With Blenrep's revival, GSK dials up long-term sales goal—again—despite RSV vaccine woes
Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...
Why GSK Stock Is Surging Today
GSK generated earnings per share of 23.2 pence last quarter, versus analysts’ average estimate of 20 pence. Last quarter, its ...
GSK, gold miners shares push Britain's FTSE 100 higher
UK's FTSE 100 firmed on Wednesday after two straight days of losses, buoyed by gains in shares of heavyweight GSK and gold ...
FierceBiotech10h
GSK drops one potential 'functional cure' for hep B as it goes all-in on bepirovirsen
GSK is prioritizing development of its hepatitis B treatment bepirovirsen as the pharma ends work on another potential ...
BioSpace6h
GSK Looks to Deal in Cancer, Respiratory, Inflammation in 2025
Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...
pharmaphorum7h
GSK rides out vaccine sales weakness with cancer, HIV gains
GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics ...
GSK sees FY25 core EPS growth 6%-8%
GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...
GSK launches £2bn buyback on strong HIV and cancer drugs sales
GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines including cancer and HIV drugs, sending shares up as much as 6 per cent on ...
GSK rises Wednesday, outperforms market
GSK PLC closed 18.56% below its 52-week high of £18.24, which the company reached on May 16th.